Novo Nordisk (NYSE:NVO) inks a three-year agreement with bluebird bio (NASDAQ:BLUE) aimed at developing next-generation genome editing therapies for genetic disorders, including hemophilia. The collaborative research will leverage BLUE's proprietary mRNA-based megaTAL technology with NVO's hemophilia portfolio. The initial focus will be on correcting Factor VIII deficiency.
Financial terms are not disclosed.
Now read: Amyris - On Life Support By John Doerr »
Subscribe for full text news in your inbox